Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Figure 7

The expression of TLR3, NF-κB, casepase-8 and IFN-γ in the tumors. (A) The mRNA levels of TLR3, NF-κB, casepase-8 and IFN-γ; (B) TLR3 and NF-κB protein levels in liver tumors determined by Western Blot. Densitometric analyses of TLR3 and NF-κB proteins relative to β-actin. Values are normalized to control cells (1.00). *, p < 0.05 compared to the PBS control group; #, p < 0.05 compared to BM-06 plus sprafenib group; (C) Western blot showing the bands of TLR3 and IFN-γ proteins.

Back to article page